We Claim:

1. A pharmaceutical composition comprising 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin2-yl)benzoic acid and a pharmaceutically acceptable carrier.

2. A method of treating cystic fibrosis in a mammal comprising administering to the mammal an effective amount of 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropane carboxamido)-3-methylpyridin2-yl)benzoic acid.

3. The method of claim 2, wherein the method comprises administering an additional therapeutic agent.

4. A kit comprising 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarbox- amido)-3-methylpyridin2-yl)benzoic acid and instructions for use thereof.

5. A process for preparing the 3-(6-(1-(2,2-Difluorobenzo[d][1,3]dioxol-5-yl)cyclopro-panecarboxamido)-3-methylpyridin2-yl)benzoic acid comprising suspending or dissolving the HC1 salt of 3-(6-(1-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarboxamido)-3methyl pyridin-2-yl)benzoic acid in an appropriate solvent for an effective amount of time.

6. The process of claim 5, wherein the appropriate solvent is water or 50% methanol/water mixture.

7. The process of claim 5, wherein the appropriate solvent is water.

8. The process of claim 5, wherein the effective amount of time is 2 to 24 hours.

9. The process of claim 5, wherein the effective amount of time is 2 to 6 hours.

10. A crystal form of 3-(6-(l-(2,2-difluorobenzo[d][l,3]dioxol-5-yl)cyclopropanecarbox- amido)-3-methylpyridin-2-yl)benzoic acid having a monoclinic crystal system, a $P2_1/n$ space group, and the following unit cell dimensions:

a = 4.9626 (7) Å $\alpha = 90°$
b = 12.2994 (18) Å $\beta = 93.938\ (9)°$
c = 33.075 (4) Å $\gamma = 90°$.

## CLAIMS

1. A pharmaceutical composition comprising 3-(6-(1-(2,2-Difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid characterized as Form I and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, which further comprises an additional therapeutic agent.

3. The pharmaceutical composition of claim 2, wherein the additional therapeutic agent is selected from a mucolytic agent, a bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator that is not 3-(6-(1-(2,2-Difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid , and a nutritional agent.

4. The pharmaceutical composition of claims 2 or 3, wherein the additional therapeutic agent is N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide.